Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older

Zostavax has been shown to be efficacious in the prevention of herpes zoster and generally well tolerated in clinical trials among subjects 60 years old or older. This prespecified combined analysis from two studies compares the levels of immunogenicity and safety of Zostavax in subjects 50 to 59 ye...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Sutradhar, Santosh C., Wang, William W. B., Schlienger, Katia, Stek, Jon E., Xu, Jin, Chan, Ivan S. F., Silber, Jeffrey L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society for Microbiology (ASM) 2009
Onderwerpen:
Vaccine Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2681586/
https://ncbi.nlm.nih.gov/pubmed/19261769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00407-08
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items